本文關(guān)鍵詞： 雌孕激素受體 p53抑癌基因 卵巢上皮癌 免疫組化　出處：《山西醫(yī)科大學(xué)》2015年碩士論文　論文類型：學(xué)位論文

【摘要】：目的:本實(shí)驗(yàn)運(yùn)用免疫組織化學(xué)技術(shù)分析探討雌激素受體(ER)、孕激素受體(PR)、p53抑癌基因蛋白于上皮性卵巢惡性腫瘤的不同臨床期別、不同的病理分級(jí)及不同卵巢病理臨床類型中的分布情況及表達(dá)狀態(tài),以此初步探討雌激素受體(ER)、孕激素受體(PR)及p53蛋白在卵巢上皮惡性腫瘤的發(fā)生發(fā)展中的臨床意義及臨床檢測價(jià)值,為臨床治療卵巢癌提供新思路及基礎(chǔ)理論支持。方法:本次試驗(yàn)研究收集標(biāo)本為來源于山西醫(yī)科大學(xué)附屬第一臨床醫(yī)學(xué)院婦科2009-2012年有完整的臨床隨訪資料的45例術(shù)后病理證實(shí)為卵巢上皮性惡性腫瘤患者的常規(guī)石蠟標(biāo)本;運(yùn)用免疫組織化學(xué)的技術(shù)定性測定雌激素受體(ER)、孕激素受體(PR)、p53蛋白的陽性表達(dá)情況。積極探討分析雌孕激素受體及p53蛋白與卵巢上皮性腫瘤各種病理組織學(xué)類型、不同組織學(xué)分級(jí)及各個(gè)臨床期別階段的關(guān)系。結(jié)果:1.在所選取的45例上皮性卵巢惡性腫瘤患者病例中,雌激素受體(ER)、孕激素受體(PR)、p53蛋白的陽性表達(dá)率分別為55.56%、62.22%、62.2%。2.p53基因蛋白陽性表達(dá)提示臨床預(yù)后較差,與臨床分期關(guān)系密切,臨床分期Ⅲ、Ⅳ期p53基因陽性率表達(dá)明顯高于Ⅰ、Ⅱ期,即陽性率與臨床分期呈正相關(guān),(分別為Ⅰ-Ⅱ期32.14%,Ⅲ-Ⅳ期70.59%,差異有統(tǒng)計(jì)學(xué)意義)。3.孕激素受體(PR)陽性表達(dá)與腫瘤的分化級(jí)別及患者的臨床分期有著密切的關(guān)系。PR在Ⅰ-Ⅱ期的陽性率高于Ⅲ-Ⅳ期,分別為75%、35.29%,差異有統(tǒng)計(jì)學(xué)意義。在低分化腫瘤中的陽性表達(dá)為50%,在高-中分化腫瘤中的陽性表達(dá)為84%,差異有統(tǒng)計(jì)學(xué)意義。結(jié)論:雌激素受體(ER)、孕激素受體(PR)及p53蛋白在卵巢上皮性癌中表達(dá)較普遍,為常見現(xiàn)象。p53蛋白異常表達(dá)的程度與腫瘤的分化級(jí)別及患者的臨床分期有著密切的關(guān)系,研究發(fā)現(xiàn)p53陽性表達(dá)越高,患者在臨床分期中的級(jí)別就越晚,生物學(xué)行為及臨床上患者的病情就會(huì)越差。孕激素受體(PR)陽性表達(dá)與腫瘤的分化級(jí)別及患者的臨床分期有著密切的關(guān)系。雌激素受體(ER)、孕激素受體(PR)聯(lián)合p53蛋白的檢測對(duì)于臨床評(píng)估卵巢癌患者的預(yù)后及指導(dǎo)開展腫瘤內(nèi)分泌治療及基因治療有一定的價(jià)值。
[Abstract]:Objective: to investigate the different clinical stages of estrogen receptor ERA, progesterone receptor PPRP p53 tumor suppressor gene protein in epithelial ovarian malignant tumors by immunohistochemical technique. The distribution and expression of estrogen receptor (ERR) were studied in different pathological grades and different clinical types of ovarian pathology. The clinical significance and clinical value of progesterone receptor PRA and p53 protein in the occurrence and development of ovarian epithelial malignant tumor. Methods: to provide new ideas and basic theoretical support for clinical treatment of ovarian cancer. In this study, 45 cases of ovarian epithelial malignancy confirmed by pathology were collected from the first Clinical Medical College affiliated to Shanxi Medical University from 2009 to 2012 with complete clinical follow-up data. Conventional paraffin wax specimens of tumor patients; The estrogen receptor ERA and progesterone receptor PRA were determined by immunohistochemical technique. Positive expression of p53 protein. Positive analysis of estrogen and progesterone receptor p53 protein and ovarian epithelial tumor of various types of histopathology. The relationship between different histological grades and clinical stages. Results 1. Among 45 patients with epithelial ovarian malignant tumor, estrogen receptor ERA and progesterone receptor PRA were selected. The positive expression rates of p53 protein were 55.56 and 62.22, respectively. 2. The positive expression of p53 gene protein suggested that the clinical prognosis was poor and was closely related to clinical stage. The positive rate of p53 gene expression in clinical stage 鈪，

本文編號(hào)：1458970